Montelukast and Coronavirus Disease 2019: A Scoping Review

Iran J Allergy Asthma Immunol. 2021 Aug 7;20(4):384-393.


Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19. Montelukast (MK) is a safe asthma controller drug, which is considered as a potential antiviral drug for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This review has a systematic approach to investigate the reports on the use of MK as a part of treatment or a prophylactic agent in COVID-19. The search was conducted in PubMed, Web of Science, and Scopus databases and yielded 35 studies containing the influence of MK on SARS-CoV-2. Ultimately, MK appears to be worth being used as an adjuvant therapeutic and prophylactic drug against SARS-CoV-2. Nevertheless, more clinical trials are required to accurately investigate its effectiveness.

Keywords: COVID-19; Leukotriene D4 receptor; Leukotriene antagonists; Montelukast; SARS-CoV-2.

Publication types

  • Review

MeSH terms

  • Acetates / therapeutic use*
  • Antiviral Agents / therapeutic use
  • COVID-19 / prevention & control
  • COVID-19 Drug Treatment*
  • Cyclopropanes / therapeutic use*
  • Humans
  • Leukotriene Antagonists / therapeutic use*
  • Quinolines / therapeutic use*
  • SARS-CoV-2
  • Sulfides / therapeutic use*
  • Treatment Outcome


  • Acetates
  • Antiviral Agents
  • Cyclopropanes
  • Leukotriene Antagonists
  • Quinolines
  • Sulfides
  • montelukast